Peter Wostyn: Difference between revisions
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(expanded) |
(expanded) |
||
| Line 1: | Line 1: | ||
{{NeedsImage}} | {{NeedsImage}} | ||
'''Peter Wostyn''', MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, [[Belgium]]<ref>{{Cite web|url=https://www.linkedin.com/in/peter-wostyn-a43a07171/|title=Peter Wostyn|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=2019-10-22|website=LinkedIn|archive-url=|archive-date=|dead-url=|access-date=}}</ref> and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.<ref>{{Cite web|url=https://www.px-medical.be/en/|title=Technology - P&X Medical|website=www.px-medical.be|language=en|access-date=2019-10-22}}</ref> | '''Peter Wostyn''', MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, [[Belgium]]<ref>{{Cite web|url=https://www.linkedin.com/in/peter-wostyn-a43a07171/|title=Peter Wostyn|last=|first=|authorlink=|last2=|first2=|authorlink2=|date=2019-10-22|website=LinkedIn|archive-url=|archive-date=|dead-url=|access-date=}}</ref> and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.<ref>{{Cite web|url=https://www.px-medical.be/en/|title=Technology - P&X Medical|website=www.px-medical.be|language=en|access-date=2019-10-22}}</ref> | ||
Dr Wostyn developed the glymphatic dysfunction hypothesis which postulates that a dysfunction of the waste clearance system, called the glymphatic system, causes a build-up of toxins within the central nervous system, which precipitates at least some cases of chronic fatigue syndrome.<ref name=":0" /> | |||
==Notable studies== | ==Notable studies== | ||
* 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy<ref>{{Cite journal|last=Wostyn|first=Peter|author-link=|last2=De Deyn|first2=Peter Paul|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Sep 2018|title=The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy|url=https://linkinghub.elsevier.com/retrieve/pii/S0306987718305486|journal=Medical Hypotheses|language=en|volume=118|issue=|pages=142–145|doi=10.1016/j.mehy.2018.07.007|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [[pubmed:30037603|(Abstract)]] | * 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy<ref name=":0">{{Cite journal|last=Wostyn|first=Peter|author-link=|last2=De Deyn|first2=Peter Paul|author-link2=|last3=|first3=|author-link3=|last4=|first4=|author-link4=|last5=|first5=|author-link5=|last6=|first6=|author-link6=|last7=|first7=|last8=|first8=|date=Sep 2018|title=The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy|url=https://linkinghub.elsevier.com/retrieve/pii/S0306987718305486|journal=Medical Hypotheses|language=en|volume=118|issue=|pages=142–145|doi=10.1016/j.mehy.2018.07.007|pmc=|pmid=|access-date=|quote=|via=}}</ref> - [[pubmed:30037603|(Abstract)]] | ||
*2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction<ref>{{Cite journal|last=Wostyn|first=Peter|date=2019-10-04|title=Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction|url=https://www.ncbi.nlm.nih.gov/pubmed/31622921|journal=Medical Hypotheses|volume=134|pages=109416|doi=10.1016/j.mehy.2019.109416|issn=1532-2777|pmid=31622921}}</ref> | *2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction<ref>{{Cite journal|last=Wostyn|first=Peter|date=2019-10-04|title=Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction|url=https://www.ncbi.nlm.nih.gov/pubmed/31622921|journal=Medical Hypotheses|volume=134|pages=109416|doi=10.1016/j.mehy.2019.109416|issn=1532-2777|pmid=31622921}}</ref> | ||
| Line 14: | Line 16: | ||
==See also== | ==See also== | ||
* [[Glymphatic dysfunction hypothesis]] | |||
==Learn more== | ==Learn more== | ||
Revision as of 21:56, October 22, 2019
Peter Wostyn, MD, works in the Department of Psychiatry, Psychiatrisch Centrum Sint-Amandus, Beernem, Belgium[1] and is a co-founder of P&X Medical, a biotech company focused on the treatment of intracranial pressure, cerebrospinal fluid turnover and glymphatic flow in neurodegenerative disorders, with a primary focus on glaucoma.[2]
Dr Wostyn developed the glymphatic dysfunction hypothesis which postulates that a dysfunction of the waste clearance system, called the glymphatic system, causes a build-up of toxins within the central nervous system, which precipitates at least some cases of chronic fatigue syndrome.[3]
Notable studies[edit | edit source]
- 2018, The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy[3] - (Abstract)
- 2019, Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction[4]
Talks and interviews[edit | edit source]
Online presence[edit | edit source]
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ "Peter Wostyn". LinkedIn. October 22, 2019. Cite has empty unknown parameter:
|dead-url=(help) - ↑ "Technology - P&X Medical". www.px-medical.be. Retrieved October 22, 2019.
- ↑ 3.0 3.1 Wostyn, Peter; De Deyn, Peter Paul (September 2018). "The putative glymphatic signature of chronic fatigue syndrome: A new view on the disease pathogenesis and therapy". Medical Hypotheses. 118: 142–145. doi:10.1016/j.mehy.2018.07.007.
- ↑ Wostyn, Peter (October 4, 2019). "Retinal nerve fiber layer thinning in chronic fatigue syndrome as a possible ocular biomarker of underlying glymphatic system dysfunction". Medical Hypotheses. 134: 109416. doi:10.1016/j.mehy.2019.109416. ISSN 1532-2777. PMID 31622921.
